These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36209319)

  • 1. Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophy.
    Zang J; Johannsen J; Denecke J; Weiss D; Koseki JC; Nießen A; Müller F; Nienstedt JC; Flügel T; Pflug C
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1329-1338. PubMed ID: 36209319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
    van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectory of change in the swallowing status in spinal muscular atrophy type I.
    Choi YA; Suh DI; Chae JH; Shin HI
    Int J Pediatr Otorhinolaryngol; 2020 Mar; 130():109818. PubMed ID: 31945686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies.
    Leon-Astudillo C; Brooks O; Salabarria SM; Coker M; Corti M; Lammers J; Plowman EK; Byrne BJ; Smith BK
    Pediatr Pulmonol; 2024 May; 59(5):1364-1371. PubMed ID: 38358081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment.
    McGrattan KE; Shell RD; Hurst-Davis R; Young SD; O'Brien E; Lavrov A; Wallach S; LaMarca N; Reyna SP; Darras BT
    J Neuromuscul Dis; 2023; 10(4):531-540. PubMed ID: 37092232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
    Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
    J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
    Pascual-Morena C; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Martínez-Vizcaíno V
    Hum Gene Ther; 2023 Feb; 34(3-4):129-138. PubMed ID: 36136906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module.
    Berti B; Fanelli L; de Sanctis R; Onesimo R; Palermo C; Leone D; Carnicella S; Norcia G; Forcina N; Coratti G; Giorgio V; Cerchiari A; Lucibello S; Finkel R; Pane M; Mercuri E
    J Neuromuscul Dis; 2021; 8(4):589-601. PubMed ID: 34024771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.
    Shell RD; McGrattan KE; Hurst-Davis R; Young SD; Baranello G; Lavrov A; O'Brien E; Wallach S; LaMarca N; Reyna SP; Darras BT
    Neuromuscul Disord; 2023 Aug; 33(8):670-676. PubMed ID: 37455203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swallowing Problems in Spinal Muscular Atrophy Types 2 and 3: A Clinical, Videofluoroscopic and Ultrasound Study.
    van der Heul AMB; Nievelstein RAJ; van Eijk RPA; Asselman F; Erasmus CE; Cuppen I; Bittermann AJN; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2023; 10(3):427-438. PubMed ID: 37005890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
    Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
    Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DySMA - an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing.
    Zang J; Witt S; Johannsen J; Weiss D; Denecke J; Dumitrascu C; Nießen A; Quitmann JH; Pflug C; Flügel T
    J Neuromuscul Dis; 2024; 11(2):473-483. PubMed ID: 38457144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and psychometric properties of the Turkish version of Neuromuscular disease Swallowing Status Scale (NdSSS) in patients with oro-pharygo-esophageal dysphagia in neuromuscular disorders.
    Sakin YS; Umay E; Tanoglu A; Erdal H; Koc G; Gundogdu I
    Acta Gastroenterol Belg; 2022; 85(1):21-27. PubMed ID: 35304990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.